Respiratory and Hemodynamic Implications of Endoscopic Myotomy of the Esophagus and Stomach
Launched by CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS · Oct 27, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of certain endoscopic treatments, specifically peroral endoscopic myotomy (POEM) and gastric peroral endoscopic myotomy (GPOEM), on breathing and blood pressure in patients with conditions like esophageal achalasia and gastroparesis. The researchers want to understand if there are specific factors that could predict complications during general anesthesia and how changes in pressure within the abdomen might affect a patient’s breathing and blood flow during these procedures.
If you are at least 18 years old and classified as having a low to moderate risk for anesthesia (ASA classification 1 to 3), you may be eligible to participate. Participants will receive standard care for their treatment and will not have to follow any special rules beyond what is usual for this procedure. It's important to note that individuals who have difficulty following study procedures due to language or mental health issues may not be able to take part in this trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Completed and signed consent form (consent form attached)
- • Age ≥ 18 years old
- • Anesthetic risk classification according to ASA, from 1 to 3
- • Patients summoned for POEM or GPOEM type endoscopy treatment
- Exclusion Criteria:
- • - Inability to follow study procedures, eg. due to language problems, psychological disorders, dementia, etc. of the participant
About Centre Hospitalier Universitaire Vaudois
The Centre Hospitalier Universitaire Vaudois (CHUV) is a leading academic medical center located in Lausanne, Switzerland, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUV plays a pivotal role in translating scientific discoveries into transformative therapies, enhancing patient care across a diverse range of medical disciplines. With a multidisciplinary team of experts and state-of-the-art facilities, CHUV is dedicated to fostering collaboration and delivering high-quality evidence that informs clinical practice and policy.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lausanne, Vaud, Switzerland
Patients applied
Trial Officials
Madeleine Chollet-Rivier
Principal Investigator
University of Lausanne Hospitals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials